Sanofi Initiates Vaccine Study in Canada - Analyst Blog

By
A A A

Sanofi 's ( SNY ) vaccines division, Sanofi Pasteur, recently announced that Cdiffense, a phase III program, has been initiated. Sanofi is working on developing a vaccine for the prevention of primary symptomatic clostridium difficile infection (CDI). The program aims to assess the safety, efficacy and immunogenicity of the CDI vaccine.

In Canada, Sanofi has started enrolling volunteers for the randomized, observer-blind, placebo-controlled, multi-center, multi-national (across 17 countries), phase III trial. The trial will enroll up to 15,000 volunteers aged ≥ 50 years, who have received systemic antibiotics in the past year and are planning to be hospitalized or were hospitalized at least twice before.

Earlier this year, Sanofi's vaccine portfolio received a boost when the European Commission approved its 6-in-1 pediatric vaccine Hexyon/Hexacima (DTaP-IPV-Hib-HepBvaccine).


The 6-in-1 vaccine is indicated for the prevention of diphtheria, tetanus, pertussis (whooping cough), hepatitis B, poliomyelitis and invasive infections caused by haemophilus influenzaetype b in infants.

We note that Sanofi possesses one of the world's leading vaccine operations, with total sales of €3.9 billion in 2012. The company's portfolio includes pediatric vaccines, influenza vaccines, adult and adolescent booster vaccines, meningitis vaccines, and travel and endemic vaccines. Sanofi also has a strong position in both seasonal and pre-pandemic influenza vaccines. Sanofi continues to expand its vaccine business. We expect a significant ramp in vaccine sales over the next several years.

Sanofi carries a Zacks Rank #5 (Strong Sell). We are concerned about generic erosion confronting most of Sanofi's key drugs. Additionally, recent pipeline failures (oncology candidate -  iniparib and anticoagulant - otamixaban) have put immense pressure on Sanofi's pipeline.

At present, companies like Actelion Ltd. ( ALIOF ), Biogen Idec ( BIIB ) and Gilead Sciences, Inc. ( GILD ) look well-positioned with all three being Zacks Rank #1 (Strong Buy) stocks.



ACTELION LTD (ALIOF): Get Free Report

BIOGEN IDEC INC (BIIB): Free Stock Analysis Report

GILEAD SCIENCES (GILD): Free Stock Analysis Report

SANOFI-AVENTIS (SNY): Free Stock Analysis Report

To read this article on Zacks.com click here.

Zacks Investment Research



The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.




This article appears in: Investing , Business , Stocks

Referenced Stocks: ALIOF , BIIB , CDI , GILD , SNY

Zacks.com

Zacks.com

More from Zacks.com:

Related Videos

Stocks

Referenced

Most Active by Volume

45,543,019
  • $16.75 ▲ 0.12%
44,349,390
  • $132.54 ▲ 0.88%
32,695,176
  • $3.01 ▲ 19.92%
28,073,679
  • $34.76 ▲ 2.75%
27,339,999
  • $9.15 ▼ 3.58%
26,142,754
  • $34.71 ▼ 1.03%
25,357,890
  • $46.90 ▼ 1.10%
24,562,443
  • $15.27 ▼ 1.55%
As of 5/22/2015, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com